Professional Documents
Culture Documents
This process is most applicable to strategic management at the business unit level of the
organization. For large corporations, strategy at the corporate level is more concerned with
managing a portfolio of businesses. For example, corporate level strategy involves decisions
about which business units to grow, resource allocation among the business units, taking
advantage of synergies among the business units, and mergers and acquisitions. In the process
outlined here, "company" or "firm" will be used to denote a single-business firm or a single
business unit of a diversified firm.
Once the firm has specified its objectives, it begins with its current situation to devise a strategic
plan to reach those objectives. Changes in the external environment often present new
opportunities and new ways to reach the objectives. An environmental scan is performed to
identify the available opportunities. The firm also must know its own capabilities and limitations
in order to select the opportunities that it can pursue with a higher probability of success. The
situation analysis therefore involves an analysis of both the external and internal environment.
The external environment has two aspects: the macro-environment that affects all firms and a
micro-environment that affects only the firms in a particular industry. The macro-environmental
analysis includes political, economic, social, and technological factors and sometimes is referred
to as a PEST analysis.
2.1. Appropriate Tools to analyse Current business Plan
What next? This is the question on the minds of the shareholders. We have drawn up a growth
blueprint for the company, segregated into short and medium-term business drivers focusing on
ramping up of the existing business verticals, creating front-end marketing organisations and
entering new high-growth product segments. In the short term, we have identified key areas
which will drive business growth for your company. We will cater to the API needs of Hospira
and other global innovators in addition to our regular API and formulation sales in the emerging
markets. We will strengthen our geographical presence in key regulated markets like the US,
Europe and Japan. Currently, we are marketing around 10 products in the oral cephalosporins
segment and 5 products in the NPNC (Non-penicillin, Non-cephalosporin) segment. Your
company will further strengthen its product basket for catering to these markets.
Our focus on acquiring front-end marketing companies possessing infrastructure, people, product
registrations and approvals will augur well in the medium term. Our product pipeline in the
regulated markets will be filled with our own molecules, ANDAs and in-licensed products. This
will help us strengthen our product basket and maximise and internalise value which was earlier
shared with our marketing partners.
sizeable debt burden which weighed heavy on your companys profitability. With the debt levels
coming down and with a strong growth strategy in place, this is set to change going forward.
LLC, a US-based generic marketing and sales services company through an all-cash deal for
creating a front-end presence in the US market to deliver generic products to the US customers
directly. Karalex Pharma is a leading provider of generic pharmaceuticals, focused exclusively
on the US healthcare market.
Valuing People
We value individuality and creativity. Our unique People and Process Paradigm helps achieve
the twin objective emphasis on regulatory and compliance on one hand, while fostering
innovation and creativity on the other.
Peak Performance
We seek to build a sustainable organisational eco-system where one is constantly motivated to
attain new heights and empowered to discover new avenues for growth.
Quality
Quality has always been a strong part of Orchids proposition. Our quality initiative covers all
aspects including product quality, operational quality, environmental quality and finally a good
quality of life for our people.